Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Byfavo (remimazolam) is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• Propofol vs. Remimazolam: In elderly patients undergoing gastrointestinal procedures, propofol demonstrated a significantly faster time to loss of consciousness and higher initial sedation success compared to remimazolam, despite remimazolam showing a superior safety profile.
• Remimazolam vs. Midazolam: Remimazolam was more effective than midazolam, leading to reduced need for additional doses and better procedural success in colonoscopy patients and general procedural sedation.
• Sedative Efficiency: Remimazolam exhibited higher sedative efficiency than placebo and midazolam but was less effective than propofol in endoscopic procedures.
• Remimazolam consistently exhibited a significantly lower incidence of adverse events, including respiratory depression, hypoxemia, bradycardia, dizziness, injection site pain, nausea, and hypotension, when compared to propofol across various studies.
• In comparisons with midazolam, remimazolam demonstrated comparable overall adverse event rates but showed improved cognitive recovery and reduced need for rescue medication, with specific adverse events being inconclusive.